Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EAL2200
- Development stage
- Unknown
- Lead developer
- iNtRON Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Drug Delivery Systems, Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Topical
01
Overview
EAL2200 is an agricultural therapeutic candidate developed by iNtRON Biotechnology (also known as Intron Therapeutics) using a proprietary microalgae-based platform. The program is designed to address infections caused by agricultural pathogens, specifically the plant pathogen *Erwinia amylovora* (the causative agent of fire blight in pome fruits) and the foodborne/livestock pathogen *Salmonella* species. The microalgae platform likely serves as a bio-factory or delivery vehicle for antimicrobial agents, such as endolysins or other therapeutic proteins, tailored for agricultural and livestock applications. As of the current pipeline status, EAL2200 is in the early stages of development for these agricultural indications.
- Other names
- Microalgae-based EAL2200
02
Targets
PGN (Peptidoglycan)
Beyond the preview
Go deeper on EAL2200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EAL2200.